Globus Medical will announce second-quarter financial results on August 6, 2026, followed by a teleconference for investors.
Quiver AI Summary
Globus Medical, Inc. will announce its financial results for the second quarter ending June 30, 2026, after the market close on August 6, 2026. The press release, available on their investor website, will be followed by a teleconference at 4:30 p.m. Eastern Time to discuss the company's performance. Participants can join the call via a webcast or by registering for telephone access, after which they will receive details to join. Globus Medical is recognized as a leading global musculoskeletal technology company focused on addressing clinical needs in areas such as spine, orthopedic trauma, and joint reconstruction. The release includes cautionary forward-looking statements regarding potential risks and uncertainties affecting the company’s operations and performance.
Potential Positives
- Globus Medical will announce its financial results for the second quarter of 2026, showcasing transparency and commitment to shareholders.
- A teleconference will be held to discuss performance with the investment community, enhancing communication with investors.
- The availability of an audio archive after the call allows interested parties to access and review the information at their convenience.
Potential Negatives
- Forward-looking statements in the press release highlight significant uncertainties and risks, which may raise concerns among investors about the company's future performance.
- The need to register in advance for the teleconference call could limit participation from potential investors wanting to hear the financial results discussion.
FAQ
When will Globus Medical announce its second-quarter financial results?
Globus Medical will announce its financial results on August 6, 2026, after market close.
How can I access the financial results of Globus Medical?
A copy of the financial release will be available on the Globus Medical website at www.investors.globusmedical.com.
What time is the teleconference after the financial announcement?
The teleconference will be held at 4:30 p.m. Eastern Time on August 6, 2026.
How can I join the teleconference?
You can join via webcast on the Investors page or register for telephone access in advance.
Where can I find more information about Globus Medical?
Additional information can be accessed at www.globusmedical.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GMED Insider Trading Activity
$GMED insiders have traded $GMED stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $GMED stock by insiders over the last 6 months:
- KELLY HULLER (EVP, GC, Corporate Secretary) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $2,766,700.
- DAVID D DAVIDAR sold 25,000 shares for an estimated $2,019,072
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$GMED Revenue
$GMED had revenues of $759.9M in Q1 2026. This is an increase of 27.04% from the same period in the prior year.
You can track GMED financials on Quiver Quantitative's GMED stock page.
You can access data on GMED stock through the Quiver Quantitative API.
$GMED Congressional Stock Trading
Members of Congress have traded $GMED stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GMED stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 03/03.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
$GMED Hedge Fund Activity
We have seen 287 institutional investors add shares of $GMED stock to their portfolio, and 213 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MADISON AVENUE PARTNERS, LP removed 1,907,275 shares (-72.7%) from their portfolio in Q1 2026, for an estimated $164,330,814
- MILLENNIUM MANAGEMENT LLC added 1,409,031 shares (+601.3%) to their portfolio in Q1 2026, for an estimated $121,402,110
- BANK OF MONTREAL /CAN/ removed 1,066,079 shares (-31.6%) from their portfolio in Q1 2026, for an estimated $91,853,366
- PARSIFAL CAPITAL MANAGEMENT, LP removed 835,600 shares (-68.3%) from their portfolio in Q1 2026, for an estimated $71,995,296
- WALLEYE CAPITAL LLC removed 818,829 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $70,550,306
- HOLOCENE ADVISORS, LP added 773,834 shares (+inf%) to their portfolio in Q1 2026, for an estimated $66,673,537
- AQR CAPITAL MANAGEMENT LLC added 728,692 shares (+617.1%) to their portfolio in Q1 2026, for an estimated $62,784,102
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$GMED Analyst Ratings
Wall Street analysts have issued reports on $GMED in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 05/08/2026
To track analyst ratings and price targets for $GMED, check out Quiver Quantitative's $GMED forecast page.
$GMED Price Targets
Multiple analysts have issued price targets for $GMED recently. We have seen 8 analysts offer price targets for $GMED in the last 6 months, with a median target of $103.5.
Here are some recent targets:
- An analyst from BMO Capital set a target price of $94.0 on 07/09/2026
- Tom Stephan from Stifel set a target price of $80.0 on 07/08/2026
- Matt O'Brien from Piper Sandler set a target price of $100.0 on 06/15/2026
- David Saxon from Needham set a target price of $117.0 on 05/08/2026
- Larry Biegelsen from Wells Fargo set a target price of $103.0 on 05/08/2026
- Shagun Singh from RBC Capital set a target price of $120.0 on 05/08/2026
- Matt Miksic from Barclays set a target price of $123.0 on 02/25/2026
Full Release
AUDUBON, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2026 after the market close on Thursday, August 6, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com .
Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call live via webcast on the Investors page of Globus Medical’s website at https://www.investors.globusmedical.com/news-events/events-webcasts .
To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
The audio archive will be available after the call on the Investors page of the Globus Medical website.
About Globus Medical, Inc.
Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Additional information can be accessed at
www.globusmedical.com
.
Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with health epidemics, pandemics and similar outbreaks, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, the successful integration of businesses that we have acquired or may acquire in the future, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, refer to the disclosures contained in our most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”), including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our subsequent filings with the SEC. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. Except as may be required by applicable law, we undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof. As used herein, the “Company”, “Globus”, “Globus Medical”, “we”, “us”, and “our” refers to Globus Medical, Inc.
Contact
Brian Kearns
Senior Vice President, Corporate Development and Investor Relations
(610) 930-1800
[email protected]